This study is currently not recruiting participants.

PROTOCOL XSGP-302: A Phase 3 Study to Evaluate the Glucose Response of G-PEN (Glucagon Injection) in Pediatric patients with Type 1 Diabetes

Study on Medicine for Severe Low Blood Sugar in Children

Not Recruiting
2 years - 18 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to investigate a new formulation of glucagon to treat severe hypoglycemia in children.

Detailed description of study

The purpose of this study is to investigate a new formulation of glucagon to treat severe hypoglycemia in children.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: type 1 diabetes
  • Age: 2 years - 18 years
  • Gender: All

This study investigates an investigational medication for treating severe hypoglycemia in children. Severe hypoglycemia is a condition where blood sugar levels drop very low, causing symptoms like shakiness, confusion, and in severe cases, loss of consciousness.

Participants in the study will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any active medical ingredients. The study will monitor the effects and safety of the treatment.

  • Who can participate: The study is open to children aged [specific age range] who experience severe hypoglycemia.
  • Study details: Participants will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any active medical ingredients.
Updated on 19 Feb 2024. Study ID: 1701063424

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team